🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14,283 results for “B” Clear

  1. Dovato 50 mg/300 mg film-coated tablets, Truvada 200 mg/245 mg film-coated tablets, Descovy 200 mg/25 mg film-coated tablets, Combivir 150 mg/300 mg film-coated tablets, Epivir 300 mg film-coated tablets, Ziagen 300 mg film-coated tablets, Retrovir 250 mg capsules, hard, Kivexa 600 mg/300 mg film-coated tablets, Triumeq 50 mg/600 mg/300 mg film-coated tablets

    Fondazione Telethon ETS

    HIV-infected

    phase 3 small molecule active

    1 trial

  2. Doxorubicin

    Takeda

    Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  3. Doxorubicin 2 mg/ml Solution for Injection., Fibromun

    Philogen S.p.A.

    Unresectable or metastatic soft tissue sarcoma

    phase 3 small molecule active

    1 trial

  4. Doxorubicine + docetaxel sequential

    Sanofi Pasteur

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  5. Doxorubicinhydrochlorid Teva® 2 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bleomycin 15000 IU Powder for solution for injection/infusion, Detimedac 200 mg, Pulver zur Herstellung einer Injektions-/Infusionslösung, Doxorubicin hydrochloride 2 mg/ml solution for infusion, ADCETRIS 50 mg powder for concentrate for solution for infusion, Vinblastine Sulfate 1 mg/ml solution for injection, Dacarbazine medac 200 mg, powder for solution for injection/infusion, Vinblastinsulfat Teva® 1 mg/ml Injektions

    Takeda

    Advanced Classical Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  6. Doxycycline

    Hospital Authority, Hong Kong

    Tuberculosis

    phase 3 small molecule active

    1 trial

  7. Doxycycline (200mg/day) or Placebo

    United Therapeutics Europe Ltd

    Persian Gulf Syndrome

    phase 3 small molecule completed

    1 trial

  8. Doxycycline Sandoz 100 mg tabletten, Doxycycline EG 200 mg Tabletten

    The George Institute

    Sexually Transmitted Infections

    phase 3 small molecule active

    1 trial

  9. Drisapersen

    BioMarin Pharmaceutical Australia Pty Ltd

    Muscular Dystrophies

    phase 3 small molecule terminated

    2 trials

  10. Dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 3 small molecule completed

    1 trial

  11. Dronabinol Capsules

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 3 small molecule active

    1 trial

  12. Drug use prevention intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Adolescent Behavior

    phase 3 other completed

    1 trial

  13. Drug: Ivonescimab Injection

    Summit Therapeutics

    Metastatic Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  14. Duloxetine hydrochloride

    Eli Lilly and Company

    Diabetic Neuropathies

    phase 3 small molecule completed

    1 trial

  15. Dupilumab

    Regeneron UK Limited

    Eosinophilic Esophagitis (EoE)

    phase 3 small molecule active

    2 trials

  16. Dupilumab

    Regeneron UK Limited

    Lichen Simplex Chronicus

    phase 3 small molecule active

    2 trials

  17. Dupilumab

    Regeneron UK Limited

    Prurigo Nodularis

    phase 3 small molecule active

    1 trial

  18. Dupilumab

    Regeneron UK Limited

    Wheezing

    phase 3 small molecule active

    1 trial

  19. Dupilumab Prefilled Syringe

    Regeneron UK Limited

    Asthma Control

    phase 3 small molecule active

    1 trial

  20. Dupilumab SAR231893

    Regeneron UK Limited

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule completed

    2 trials

  21. Dupilumab SAR231893

    Regeneron UK Limited

    Asthma

    phase 3 small molecule completed

    1 trial

  22. Dupilumab SAR231893

    Regeneron UK Limited

    Chronic Spontaneous Urticaria

    phase 3 small molecule completed

    1 trial

  23. Dupilumab SAR231893

    Regeneron UK Limited

    Chronic Rhinosinusitis Without Nasal Polyps

    phase 3 small molecule completed

    1 trial

  24. Dupilumab SAR231893

    Regeneron UK Limited

    Cold Urticaria

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources